Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Inclusion Criteria: Age ≥18 years old, male or female Life expectancy≥12 weeks; Phase 1b: Patients with advanced solid tumors diagnosed by histology or cytology, who have been failure to previous standard treatments; Phase 2: Patients with HNSCC, NPC, OC, NSCLC, SCLC, HCC, cHL and other solid tumors diagnosed by histology or cytology, who have been failure to first-line standard treatment (including PD-1/L1) at least; ECOG PS of 0 or 1; Adequate organs function, including bone marrow, hepatic, renal, cardiac, coagulation. Adverse events associated with previous anti-tumor therapy have returned to≤ grade 1(NCI CTCAE V5.0); Exclusion Criteria: Previous treatment with CD47 inhibitor/SIRPαinhibitor or fusion protein; Patients with symptomatic or progressive central nervous system (CNS) metastasis; Uncontrolled hypertension, pulmonary hypertension or unstable angina, myocardial infarction within 6 months prior to administration; a history of chronic heart failure (NYHA G3/4); severe arrhythmia; A history of arterial thrombosis, deep venous thrombosis and pulmonary embolism within 3 months prior to administration; A history of moderate or severe dyspnea, interstitial lung disease (ILD) or servre pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency; With other malignant tumors; Diseases that may cause gastrointestinal bleeding or perforation; Uncontrollable pleural, peritoneal or pericardial effusions; A history of immunodeficiency; A history of autoimmune diseases; Uncontrolled severe active infections.